Investors are always looking for stocks that are both cheap and growing. A low P/E ratio shows when a company looks undervalued today, but the real opportunity comes when earnings are expected to grow faster than the market is pricing in.
The companies below trade at reasonable valuations while still posting strong or decent growth outlooks. That mix of low multiples and rising earnings makes them attractive picks for investors who want growth without overpaying.
The following stocks stand out for looking undervalued today, making them interesting candidates for investors looking to add undervalued growth to their portfolios without overpaying for future earnings.
| Company Name (Ticker) | P/E Ratio | Analyst Upside |
| Centene (CNC) | 17 | 20% |
| MetLife (MET) | 8 | 13% |
| Bristol-Myers Squibb (BMY) | 7 | 12% |
| Tapestry (TPR) | 18 | 12% |
| Kroger (KR) | 14 | 9% |
Unlock our Free Report: 5 undervalued compounders with upside based on Wall Street’s growth estimates that could deliver market-beating returns (Sign up for TIKR, it’s free) >>>
Centene (CNC)
Centene is a leading managed healthcare company serving Medicaid, Medicare, and marketplace members across the United States. The company has reported revenue growth, with its annual revenue for 2024 increasing by approximately 5.9%, and a total revenue increase of 13% for the twelve months ending June 30, 2025.
Its return on equity has been declining, with a recent figure of approximately 7.5%, reflecting the low-margin nature of the health insurance sector and operational challenges. Centene does not pay a dividend, choosing to reinvest its cash flow into acquisitions and operational improvements.
While the company’s scale in essential healthcare services and past expansion have made it an attractive option for long-term investors, its recent profitability and declining ROE are critical factors to consider.
Value stocks like Centene in under a minute with TIKR’s new Valuation Model (It’s free) >>>
MetLife (MET)
MetLife is a global insurance provider offering life insurance, annuities, and employee benefits to both individuals and corporations. The company’s revenue for the trailing twelve months ending March 31, 2025, increased by 8.77%, and it maintains a strong return on equity of approximately 15.93%.
MetLife trades at a price-to-earnings ratio of about 12.3, which is still lower than the broader market, suggesting a potentially attractive valuation. The company offers a dividend yield of roughly 2.9%, supported by stable cash flow, and has consistently increased dividends for 12 consecutive years.
MetLife’s diversified portfolio and its valuation make it a compelling choice for investors seeking a mix of income and value in the financial sector.
Track MetLife’s financials, growth trends, and analyst forecasts on TIKR (it’s free)>>>
Bristol-Myers Squibb (BMY)
Bristol Myers Squibb is one of the world’s largest pharmaceutical companies, best known for its oncology, immunology, and cardiovascular treatments. The company generates steady cash flow from established drugs, but its real potential lies in a pipeline of new therapies designed to offset the impact of upcoming patent expirations.
While many large pharma names trade at a premium for their pipelines, BMY’s valuation remains depressed as investors worry about near-term losses from expiring patents. That skepticism may be overdone, since the company is launching new treatments in cancer, autoimmune diseases, and cardiovascular health that could more than replace declining revenue streams. Management has also leaned on strategic acquisitions to deepen its pipeline, further strengthening the growth story.
The stock trades at a discount to both peers and the broader market, yet it still carries meaningful growth drivers through new product launches and R&D investments. If the pipeline delivers as expected, the market may eventually rerate BMY higher, rewarding investors who step in while the stock looks cheap.
See if top investors & hedge funds are buying or selling Pfizer right now (It’s free) >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
